ChronoScale Holdings Corporation held its 2026 Annual Meeting of Stockholders on November 6, 2026. Shareholders elected seven directors, ratified CBIZ CPAs P.C. as the independent auditor for fiscal year 2027, and approved executive compensation and restricted stock awards for non-employee directors.
ChronoScale Holdings reported fiscal Q1 2027 revenue of $41.5 million, a 148% year-over-year increase, following its strategic shift toward AI infrastructure. The company completed the divestiture of its legacy Ekso business and secured a major 50 MW AI compute deployment with Microsoft.
Term
Q1 2027
“We believe our strong revenue growth and expanded customer commitments validate the demand we are seeing and our opportunity to grow alongside our customers. Our Microsoft deployment and partnerships with Nutanix and Baseten should position us to serve hyperscale and enterprise AI demand, while the completed Ekso sale is intended to allow us to sharpen our focus on AI infrastructure. With our customer agreements and current deployment schedule supporting an expected $1 billion in annualized revenue run rate by calendar Q3 2027, our priority is disciplined execution and delivering the infrastructure our customers need at scale.”
Cenly Chen, Chief Executive Officer of ChronoScale
ChronoScale Holdings Corp reported a significant revenue increase to $41.5 million for the quarter ended August 31, 2026, compared to $16.7 million in the prior year, driven by its cloud computing infrastructure expansion. However, the company realized a net loss of $42.5 million, impacted by a $16.1 million loss from discontinued operations and increased stock-based compensation expenses.
Scott Davis resigned from the Board of Directors of ChronoScale Holdings Corp effective October 3, 2026, following the company's sale of its subsidiary Ekso Bionics, Inc. In connection with his departure, Davis received a lump sum cash payment of $709,500 and 51,626 fully vested restricted stock units as part of a release agreement.
ChronoScale Holdings Corporation completed the sale of its wholly owned subsidiary, Ekso Bionics, Inc., to focus resources on its core AI infrastructure business. In connection with the divestiture, Ekso's COO Jason C. Jones was terminated and received a severance package totaling approximately $0.24 million. The company also announced new AI infrastructure contracts expected to drive an annualized revenue run rate of $1 billion by Q3 2027.